GlassScriptPhysician profile
Stephen Allen Klein
NPI 1831257872
$1,234.31
in general payments reported to CMS, 2019-2025
26 companies · $61.37 in 2025
The $61.37 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $265 · 2023: $588 · 2024: $320 · 2025: $61.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181.68 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $110.88 | 2023-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $107.03 | 2022-2024 | |
| Embecta Corp. | $91.62 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Mannkind Corporation | $84.99 | 2022-2024 | Afrezza |
| Corcept Therapeutics | $79.01 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.33 | 2022-2024 | Jardiance |
| Medtronic, INC. | $63.21 | 2022-2023 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.35 | 2022 | |
| Halozyme INC | $40.88 | 2023 | |
| Antares Pharma, INC. | $39.75 | 2024 | Xyosted |
| Becton, Dickinson and Company | $39.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.01 | 2024 | |
| Glaxosmithkline, LLC. | $23.72 | 2023 | Arexvy, Shingrix |
| Ultragenyx Pharmaceutical INC. | $22.62 | 2024 | Crysvita |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $22.09 | 2024 | Ilet Bionic Pancreas |
| Xeris Pharmaceuticals, INC. | $21.80 | 2023 | Recorlev |
| Endo Pharmaceuticals INC. | $21.65 | 2022 | |
| Insulet Corporation | $21.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.63 | 2024 | Strensiq |
| Alvogen INC | $18.23 | 2023 | Teriparatide |
| Ibsa Pharma INC. | $17.09 | 2023 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $15.96 | 2023 | Unithroid |
| Abbvie INC. | $15.63 | 2022 | |
| Recordati_rare_diseases_inc. | $14.07 | 2023 | Signifor Lar, Isturisa |
| Pfizer INC. | $13.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.